← Cancer trial database
Trial
Non-small cell lung cancer

Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC

Trial status

Registered, Not Yet Recruiting

Status as of

Got an update?
Trial ID
NCT07899801 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Exploratory
Location
Houston, TX (US, single-center)
Published in
New in Oncology - Nov 19, 2026

This Phase 1a/1b, open-label MD Anderson study tests concurrent zanidatamab plus zongertinib in advanced, unresectable, or metastatic non-small cell lung cancer with an activating HER2 tyrosine kinase domain mutation (including exon 20 insertions like YVMA; HER2 mutations are a small subset of NSCLC at roughly a few percent). Zanidatamab (Jazz Pharmaceuticals, originally from Zymeworks) is a HER2-directed bispecific monoclonal antibody that binds two HER2 epitopes (ECD4 and ECD2) to increase receptor clustering/internalization and immune effector activity, while zongertinib (Boehringer Ingelheim) is an oral, HER2-selective tyrosine kinase inhibitor designed to inhibit mutant HER2 signaling (including exon 20 insertion variants). Part 1 is a safety lead-in to establish tolerability of the combination; Part 2 expands at a selected regimen to look for preliminary anti-tumor activity alongside continued safety and PK. The commercial/scientific angle is “vertical” HER2 blockade (antibody + TKI) in a genomically defined lung cancer niche where response depth/duration can be limited with single-agent targeted therapy. Today’s care for metastatic HER2-mutated NSCLC includes approved HER2 TKIs such as zongertinib and sevabertinib for eligible HER2-TKD-mutated disease, with chemotherapy and trastuzumab deruxtecan among other options according to prior therapy; this trial explores whether a chemotherapy-sparing dual-HER2 strategy can improve outcomes.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →